Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Discloses CEO Kelly s Severance; Jorge Leon Lands on CytoCore s Medical Advisory Board; Eksigent and Epidauros Tap New CEOs; Myriad s Scholl Moves to Genzyme; and Others

NEW YORK, May 1 (GenomeWeb News) - Orchid Cellmark on April 26 said it had entered into a severance agreement with Paul Kelly, whom Orchid fired March 8. Terms of the agreement call for Orchid to pay Kelly $187,500 in six $31,250 monthly installments.

 

Also that day, Orchid said it has extended the time during which Chairman George Poste will serve as interim CEO. Poste will now man the helm until the company files its quarterly earnings report for the first quarter of 2006 and amends earnings reports for the second and third quarters of 2005. As that time, Thomas Bologna will formally become Orchid's president and CEO.

 

Previously, Orchid said Bolognawould replace Kelly on April 3 or until the company files its 2005 earnings reports.


Epidauros Biotechnology has appointed Michael Lutz as its new CEO, replacing Manfred Zoltobrocki. Lutz joins Epidauros from SuNyx where he most recently worked as CEO and sold its Bioanalytics business to Qiagen. He received his PhD in bio-organic chemistry from the ETH in Z rich, Switzerland.


Jorge Leon has become a member of CytoCore's medical advisory board, and Leon's consultancy, Leomics Associates, will be its consultant.

 

Leonhas a PhD in cellular and molecular biology.


MDS has hired David Spaight as president of MDS Pharma Services, effective immediately. Most recently, Spaight served as senior vice president of global sales and marketing at Fisher Scientific Products. He has a BS in chemistry and an MBA from the Universityof Michigan.


Tom Scholl has been hired by Genzyme Genetics as vice president of technology and development. He comes to Genzyme from Myriad Genetic Laboratories, where he was vice president of technology development.   

 

Scholl has a PhD in molecular and cell biology from Pennsylvania State University, and BSs in microbiology from Long IslandUniversity and the StateUniversityof New York, Plattsburgh.


Eksigent Technologies has hired David Weber as its new CEO and president. Weber, who also becomes a director, joins the company from Stratagene, where he was vice president of global marketing and business.


The Critical Path Institute has appointed Ellen Feigal as its new director of medical devices and imaging. Feigal is on sabbatical from TGen, where she is vice president of clinical sciences and deputy scientific director.

 

Feigal has a BS in biology and an MS in molecular biology and biochemistry from the Universityof California, Irvine, and an MD from UC Davis.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.